GenoType MTBDRplus assay for rapid detection of multidrug resistance in mycobacterium tuberculosis: A meta-analysis

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Bai, Yuanyuan ^a   Wang, Yueling ^a   Shao, Chunhong ^a   Hao, Yingying ^a   Jin, Yan ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; CULTURE MEDIUM; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; GOLD STANDARD; HUMAN; INTERMETHOD COMPARISON; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; GENETICS; META ANALYSIS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; ROC CURVE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84962314379     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150321     Document Type: Article

References (69)

1. World Health Organization. Global tuberculosis control 2008: surveillance, planning, financing. WHO/HTM/TB/2008.393. World Health Organization, Geneva, Switzerland. 2008.
2. World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11. World Health Organization, Geneva, Switzerland. 2013.
3. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 2001; 344 (17):1294-303. PMID: 11320389
4. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. WHO/HTM/TB/2011.6. World Health Organization, Geneva, Switzerland. 2011.
5. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009; 9(3):153-616. doi: 10.1016/S1473-3099(09)70041-6 PMID: 19246019
6. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoSOne. 2009; 4(9):e6914. doi: 10.1371/journal.pone.0006914 PMID: 19742330
7. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J. 2005; 25(3):564-9. PMID: 15738303
8. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000; 283 (19): 2537-45. PMID: 10815117
9. Affolabi D, Odoun M, Sanoussi N, Martin A, Palomino JC, Kestens L, et al. Rapid and inexpensive detection of multidrug-resistant Mycobacterium tuberculosis with the nitrate reductase assay using liquid medium and direct application to sputum samples. J Clin Microbiol. 2008; 46(10):3243-5. doi: 10.1128/JCM.00083-08 PMID: 18753346
10. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement Geneva: World Health Organization. 2008.
11. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol. 2005; 43(8):3699-3703. PMID: 16081898
12. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J. 2008; 32(5):1165-74. doi: 10.1183/09031936.00061808 PMID: 18614561
13. Drobniewski F, Cooke M, Jordan J, Casali N, Mugwagwa T, Broda A, et al. Systematic review, metaanalysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis. Health Technol Assess. 2015; 19(34):1-188. doi: 10.3310/hta19340 PMID: 25952553
14. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. doi: 10.7326/0003-4819-155-8-201110180-00009 PMID: 22007046
15. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med.1993; 12 (14):1293-316. PMID: 8210827
16. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21 (11):1539-58. PMID: 12111919
17. Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol. 2007; 45(8):2635-40. PMID: 17537937
18. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med. 2008; 177(7):787-92. doi: 10.1164/rccm.200709-1436OC PMID: 18202343
19. Causse M, Ruiz P, Gutierrez JB, Zerolo J, Casal M. Evaluation of new GenoType MTBDRplus for detection of resistance in cultures and direct specimens of Mycobacterium tuberculosis. Int JTuberc Lung Dis. 2008; 12(12):1456-60. PMID: 19017457
20. Lacoma A, Garcia-Sierra N, Prat C, Ruiz-Manzano J, Haba L, Rosés S, et al. GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol. 2008; 46(11):3660-7. doi: 10.1128/JCM.00618-08 PMID: 18784319
21. Huang WL, Chen HY, Kuo YM, Jou R. Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol. 2009; 47(8):2520-4. doi: 10.1128/JCM.02499-08 PMID: 19494067
22. Macedo R, Amorim A, Pereira E. Multidrug-resistant tuberculosis: rapid molecular detection with MTBDRplus assay in clinical samples. Rev Port Pneumol. 2009; 15(3):353-65. PMID: 19401789
23. Nikolayevskyy V, Balabanova Y, Simak T, Malomanova N, Fedorin I, Drobniewski F. Performance of the Genotype MTBDRPlus assay in the diagnosis of tuberculosis and drug resistance in Samara, Russian Federation. BMC Clin Pathol. 2009; 9: 2. doi: 10.1186/1472-6890-9-2 PMID: 19284561
24. Albert H, Bwanga F, Mukkada S, Nyesiga B, Ademun JP, Lukyamuzi G, et al. Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC Infect Dis. 2010; 26(10):41.
25. Anek-Vorapong R, Sinthuwattanawibool C, Podewils LJ, McCarthy K, Ngamlert K, Promsarin B, et al. Validation of the GenoType MTBDRplus assay for detection of MDR-TB in a public health laboratory in Thailand. BMC Infect Dis. 2010; 20(10):123.
26. Huyen MN, Tiemersma EW, Lan NT, Cobelens FG, Dung NH, Sy DN, et al. Validation of the GenoType MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam. BMC Infect Dis. 2010; 10:149. doi: 10.1186/1471-2334-10-149 PMID: 20525271
27. Dubois Cauwelaert N, Ramarokoto H, Ravololonandriana P, Richard V, Rasolofo V. DNA extracted from stained sputum smears can be used in the MTBDRplus assay. J Clin Microbiol. 2011; 49 (10):3600-3. doi: 10.1128/JCM.00745-11 PMID: 21832013
28. Khadka JB, Rai SK, Shrestha S, Maharjan B, Bhatta DR, Ghimire P. Study of rifampicin and isoniazid resistance mutation genes of M. tuberculosis isolates in Nepal. Nepal Med Coll J. 2011; 13(3):147-51. PMID: 22808802
29. Rigouts L, Hoza AS, De Rijk P, Torrea G, Chonde TM, Basra D, et al. Evaluation of the Genotype MTBDRplus assay as a tool for drug resistance surveys. Int JTuberc Lung Dis. 2011; 15(7):959-65. doi: 10.5588/ijtld.10.0515 PMID: 21682972
30. Imperiale BR, Zumárraga MJ, Weltman G, Zudiker R, Cataldi AA, Morcillo NS. First evaluation in Argentina of the GenoType MTBDRplus assay for multidrug-resistant Mycobacterium tuberculosis detection from clinical isolates and specimens. Rev Argent Microbiol. 2012; 44(4):283-9. PMID: 23267627
31. Crudu V, Stratan E, Romancenco E, Allerheiligen V, Hillemann A, Moraru N. First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances. J Clin Microbiol. 2012; 50(4):1264-9. doi: 10.1128/JCM.05903-11 PMID: 22301019
32. Dorman SE, Chihota VN, Lewis JJ, van derMeulen M, Mathema B, Beylis N, et al. Genotype MTBDRplus for direct detection of Mycobacterium tuberculosis and drug resistance in strains from gold miners in South Africa. J Clin Microbiol. 2012; 50(4):1189-94. doi: 10.1128/JCM.05723-11 PMID: 22238443
33. Farooqi JQ, Khan E, Alam SM, Ali A, Hasan Z, Hasan R. Line probe assay for detection of rifampicin and isoniazid resistant tuberculosis in Pakistan. J Pak Med Assoc. 2012; 62(8):767-72. PMID: 23862246
34. Jin J, Zhang Y, Fan X, Diao N, Shao L, Wang F, et al. Evaluation of the GenoType MTBDRplus assay and identification of a rare mutation for improving MDR-TB detection. Int JTuberc Lung Dis.2012; 16 (4):521-6. doi: 10.5588/ijtld.11.0269 PMID: 22325117
35. Mironova S, Pimkina E, Kontsevaya I, Nikolayevskyy V, Balabanova Y, Skenders G, et al. Performance of the GenoType MTBDRPlus assay in routine settings: a multicenter study. Eur J Clin Microbiol Infect Dis. 2012; 31(7):1381-7. doi: 10.1007/s10096-011-1453-1 PMID: 22037774
36. Raveendran R, Wattal C, Oberoi JK, Goel N, Datta S, Prasad KJ. Utility of GenoType MTBDRplus assay in rapid diagnosis of multidrug resistant tuberculosis at a tertiary care centre in India. Indian J Med Microbiol. 2012; 30(1):58-63. doi: 10.4103/0255-0857.93034 PMID: 22361762
37. Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. BMC Infect Dis. 2012; 12:37. doi: 10.1186/1471-2334-12-37 PMID: 22325147
38. Tukvadze N, Kempker RR, Kalandadze I, Kurbatova E, Leonard MK, Apsindzelashvili R, et al. Use of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosis. PLoSOne. 2012; 7(2):e31563. doi: 10.1371/journal.pone.0031563 PMID: 22347495
39. Ferro BE, García PK, Nieto LM, van Soolingen D. Predictive value of molecular drug resistance testing of Mycobacterium tuberculosis isolates in Valle del Cauca, Colombia. J Clin Microbiol. 2013; 51 (7):2220-4. doi: 10.1128/JCM.00429-13 PMID: 23658272
40. Lyu J, Kim MN, Song JW, Choi CM, Oh YM, Lee SD, et al. GenoType MTBDRplus assay detection of drug-resistant tuberculosis in routine practice in Korea. Int J Tuberc Lung Dis. 2013; 17(1):120-4. doi: 10.5588/ijtld.12.0197 PMID: 23232012
41. Maschmann Rde A, Sá Spies F, Nunes Lde S, Ribeiro AW, Machado TR, Zaha A, et al. Performance of the GenoType MTBDRplus assay directly on sputum specimens from Brazilian patients with tuberculosis treatment failure or relapse. J Clin Microbiol. 2013; 51(5):1606-8. doi: 10.1128/JCM.00364-13 PMID: 23467605
42. Yadav RN, Singh BK, Sharma SK, Sharma R, Soneja M, Sreenivas V, et al. Comparative evaluation of GenoType MTBDRplus line probe assay with solid culture method in early diagnosis of multidrug resistant tuberculosis (MDR-TB) at a tertiary care centre in India. PLoSOne. 2013; 8(9):e72036. doi: 10.1371/journal.pone.0072036 PMID: 24039735
43. Aurin TH, Munshi SK, Kamal SM, Rahman MM, Hossain MS, Marma T, et al. Molecular approaches for detection of the multi-drug resistant tuberculosis (MDR-TB) in Bangladesh. PLoSOne. 2014; 9(6): e99810. doi: 10.1371/journal.pone.0099810 PMID: 24932706
44. Chen C, Kong W, Zhu L, Zhou Y, Peng H, Shao Y, et al. Evaluation of the GenoType() MTBDRplus line probe assay on sputum-positive samples in routine settings in China. Int JTuberc Lung Dis. 2014; 18 (9):1034-9. doi: 10.5588/ijtld.13.0857 PMID: 25189549
45. Huang WL, Hsu ZJ, Chang TC, Jou R. Rapid and accurate detection of rifampin and isoniazid-resistant Mycobacterium tuberculosis using an oligonucleotide array. Clin Microbiol Infect. 2014; 20(9):O542-9. doi: 10.1111/1469-0691.12517 PMID: 24372766
46. Kumar P, Balooni V, Sharma BK, Kapil V, Sachdeva KS, Singh S. High degree of multi-drug resistance and hetero-resistance in pulmonary TB patients from Punjab state of India. Tuberculosis (Edinb). 2014; 94(1):73-80.
47. Luetkemeyer AF, Kendall MA, Wu X, Lourenço MC, Jentsch U, Swindells S, et al. Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB. J Clin Microbiol. 2014; 52 (4):1052-9. doi: 10.1128/JCM.02639-13 PMID: 24430455
48. Raizada N, Sachdeva KS, Chauhan DS, Malhotra B, Reddy K, Dave PV, et al. A multi-site validation in India of the line probe assay for the rapid diagnosis of multi-drug resistant tuberculosis directly from sputum specimens. PLoS One. 2014; 9(2):e88626. doi: 10.1371/journal.pone.0088626 PMID: 24586360
49. Gupta R, Thakur R, Gupta P, Jalan N, Kushwaha S, Gupta M, et al. Evaluation of GenoType MTBDRplus Line Probe Assay for Early Detection of Drug Resistance in Tuberculous Meningitis Patients in India. J Glob Infect Dis. 2015; 7(1):5-10. doi: 10.4103/0974-777X.150882 PMID: 25722613
50. Smith SE, Kurbatova EV, Cavanaugh JS, Cegielski JP. Global isoniazid resistance patterns in rifam-pin-resistantand rifampin-susceptible tuberculosis. Int J Tuberc Lung Dis. 2012; 16(2):203-5. doi: 10.5588/ijtld.11.0445 PMID: 22136739
51. Kipiani M, Mirtskhulava V, Tukvadze N, Magee M, Blumberg HM, Kempker RR. Significant clinical impact of a rapid molecular diagnostic test (Genotype MTBDRplus assay) to detect multidrug-resistant tuberculosis. Clin Infect Dis. 2014; 59(11):1559-66. doi: 10.1093/cid/ciu631 PMID: 25091301
52. Bwanga F, Hoffner S, Haile M, Joloba ML. Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect Dis. 2009; 9:67. doi: 10.1186/1471-2334-9-67 PMID: 19457256
53. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev. 1995; 8(4):496-514. PMID: 8665467
54. Hazbón MH, Brimacombe M, Bobadilladel Valle M, Cavatore M, Guerrero MI, Varma-Basil M, et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2006; 50(8):2640-9. PMID: 16870753
55. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003; 56(11):1129-35. PMID: 14615004
56. Gallagher EJ. Clinical utility of likelihood ratios. Ann Emerg Med. 1998; 31(3):391-7. PMID: 9506499
57. Petitti DB. Approaches to heterogeneity in meta-analysis. Stat Med. 2001; 20(23):3625-33. PMID: 11746342
58. Guo Q, Zheng RJ, Zhu CT, Zou LL, Xiu JF, Li J, et al. Pyrosequencingforthe rapid detection of rifampi-cin resistance in Mycobacterium tuberculosis: a meta-analysis. Int J Tuberc Lung Dis. 2013; 17 (8):1008-13. doi: 10.5588/ijtld.12.0519 PMID: 23541177
59. Lijmer JG, Bossuyt PM, Heisterkamp SH. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med. 2002; 21(11):1525-37. PMID: 12111918
60. Humphrey PR. Systematic reviews of diagnostic test evaluations: what's behind the scenes? ACP J Club. 2004; 141(3):A14. PMID: 15518440
61. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, vanderMeulen JH, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA. 1999; 282(11):1061-6. PMID: 10493205
62. Tatsioni A, Zarin DA, Aronson N, Samson DJ, Flamm CR, Schmid C, et al. Challenges in systematic reviews of diagnostic technologies. Ann Intern Med. 2005; 142(12 Pt2):1048-55.
63. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet. 2007; 369(9578):2042-9. PMID: 17574096
64. Barnard M, Gey van Pittius NC, van Helden PD, Bosman M, Coetzee G, Warren RM. The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. J Clin Microbiol. 2012; 50(11):3712-6. doi: 10.1128/JCM.01958-12 PMID: 22972826
65. Traore H, Fissette K, Bastian I, Devleeschouwer M, Portaels F. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int J Tuberc Lung Dis. 2000; 4(5):481-4. PMID: 10815743
66. Chang KC, Yew WW, Zhang Y. A systematic review of rapid drug susceptibility tests for multidrug-resistant tuberculosis using rifampin resistance as a surrogate. Expert Opin Med Diagn. 2009; 3(2):99-122. doi: 10.1517/17530050802665694 PMID: 23485158
67. Arentz M, Sorensen B, Horne DJ, Walson JL. Systematic review of the performance of rapid rifampicin resistance testing for drug-resistant tuberculosis. PLoSOne. 2013; 8(10):e76533. doi: 10.1371/journal.pone.0076533 PMID: 24098523
68. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. Multidrug-resistantand extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010; 375 (9728).
69. Feng Y, Liu S, Wang Q, Wang L, Tang S, Wang J, et al. Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis. PLoSOne. 2013; 8(2):e55292. doi: 10.1371/journal.pone.0055292 PMID: 23383320